Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma

被引:4
作者
Rafael S Rios [1 ]
Kenneth I Zheng [1 ]
MingHua Zheng [1 ,2 ,3 ]
机构
[1] NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
[2] Institute of Hepatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
[3] Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China
关键词
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Liver disease; Hepatocellular carcinoma; Insulin resistance; Oxidative stress; Metabolic associated fatty liver disease;
D O I
暂无
中图分类号
R735.7 [肝肿瘤]; R575.5 [肝代谢障碍];
学科分类号
100214 ; 1002 ; 100201 ;
摘要
The emergence of non-alcoholic fatty liver disease (NAFLD) as the leading chronic liver disease worldwide raises some concerns. In particular, NAFLD is closely tied to sedentary lifestyle habits and associated with other metabolic diseases, such as obesity and diabetes. At the end of the disease spectrum, non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), representing a serious health problem to modern society. Recently, an increasing number of HCC cases originating from this progressive disease spectrum have been identified, with different levels of severity and complications. Updating the current guidelines by placing a bigger focus on this emerging cause and highlighting some of its unique features is necessary. Since, the drivers of the disease are complex and multifactorial, in order to improve future outcomes, having a better understanding of NASH progression into HCC may be helpful. The risks that can promote disease progression and currently available management strategies employed to monitor and treat NASH-related HCC make up the bulk of this review.
引用
收藏
页码:2911 / 2921
页数:11
相关论文
共 159 条
[1]   Non-invasive fibrosis assessment in non-alcoholic fatty liver disease [J].
S Rios Rafael ;
I Zheng Kenneth ;
Targher Giovanni ;
Byrne Christopher D ;
Zheng MingHua .
中华医学杂志英文版, 2020, 133 (22) :2743-2745
[2]   From NAFLD to MAFLD: a "redefining" moment for fatty liver disease [J].
Zheng Kenneth I. ;
Fan Jian-Gao ;
Shi Jun-Ping ;
Wong Vincent Wai-Sun ;
Eslam Mohammed ;
George Jacob ;
Zheng Ming-Hua .
中华医学杂志(英文版), 2020, 133 (19) :2271-2273
[3]   Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC [J].
Longo, Miriam ;
Paolini, Erika ;
Meroni, Marica ;
Dongiovanni, Paola .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
[4]  
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.[J].Bianco Cristiana;Jamialahmadi Oveis;Pelusi Serena;Baselli Guido;Dongiovanni Paola;Zanoni Irene;Santoro Luigi;Maier Silvia;Liguori Antonio;Meroni Marica;Borroni Vittorio;D’Ambrosio Roberta;Spagnuolo Rocco;Alisi Anna;Federico Alessandro;Bugianesi Elisabetta;Petta Salvatore;Miele Luca;Valenti Luca.Journal of Hepatology.2020, 4
[5]  
FDA Approval Summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma..[J].Casak Sandra J;Donoghue Martha;FashoyinAje Lola;Jiang Xiaoping;Rodriguez Lisa;Shen Yuan Li;Xu Yuan;Jiang Xiling;Liu Jiang;Zhao Hong;Pierce William F;Mehta Shubhangi;Goldberg Kirsten B;Theoret Marc R;Kluetz Paul G;Pazdur Richard;Lemery Steven J.Clinical cancer research : an official journal of the American Association for Cancer Research.2020, 7
[6]  
TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease..[J]..Oncology.2020, 2
[7]   2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights [J].
Xie, Di-Yang ;
Ren, Zheng-Gang ;
Zhou, Jian ;
Fan, Jia ;
Gao, Qiang .
HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (04) :452-463
[8]   A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement [J].
Eslam, Mohammed ;
Newsome, Philip N. ;
Sarin, Shiv K. ;
Anstee, Quentin M. ;
Targher, Giovanni ;
Romero-Gomez, Manuel ;
Zelber-Sagi, Shira ;
Wong, Vincent Wai-Sun ;
Dufour, Jean-Francois ;
Schattenberg, Joern M. ;
Kawaguchi, Takumi ;
Arrese, Marco ;
Valenti, Luca ;
Shiha, Gamal ;
Tiribelli, Claudio ;
Yki-Jarvinen, Hannele ;
Fan, Jian-Gao ;
Gronbaek, Henning ;
Yilmaz, Yusuf ;
Cortez-Pinto, Helena ;
Oliveira, Claudia P. ;
Bedossa, Pierre ;
Adams, Leon A. ;
Zheng, Ming-Hua ;
Fouad, Yasser ;
Chan, Wah-Kheong ;
Mendez-Sanchez, Nahum ;
Ahn, Sang Hoon ;
Castera, Laurent ;
Bugianesi, Elisabetta ;
Ratziu, Vlad ;
George, Jacob .
JOURNAL OF HEPATOLOGY, 2020, 73 (01) :202-209
[9]   Nivolumab for the treatment of hepatocellular carcinoma [J].
Chiew Woon, Lim ;
Joycelyn Jie Xin, Lee ;
Su Pin, Choo .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (07) :687-693
[10]   Update on NAFLD genetics: From new variants to the clinic [J].
Corpechot, Christophe ;
Rousseau, Alexandra ;
Chazouilleres, Olivier .
JOURNAL OF HEPATOLOGY, 2020, 72 (06) :1210-1211